List view / Grid view
Palbociclib has received Breakthrough Therapy designation...
10 April 2013 | By Pfizer
Palbociclib has received Breakthrough Therapy designation...
“We are very pleased with this positive recommendation on bosutinib…
18 January 2013 | By Pfizer
“We are very pleased with this positive recommendation on bosutinib by the CHMP..."
“BOSULIF is the third new medicine to be approved by…
4 September 2012 | By Pfizer
“BOSULIF is the third new medicine to be approved by the FDA in just 13 months..."
Pfizer Inc. announced the Phase 3 INTORACT trial (B1771006) did…
10 August 2012 | By Pfizer
Pfizer Inc. announced the Phase 3 INTORACT trial (B1771006) did not meet its primary endpoint...
“The CHMP’s positive opinion brings us a step closer..."
20 July 2012 | By Pfizer
“The CHMP’s positive opinion brings us a step closer..."
Detailed study results to be presented...
19 June 2012 | By Pfizer
Detailed study results to be presented...
The CHMP of the EMA has adopted a positive opinion…
25 May 2012 | By Pfizer
The CHMP of the EMA has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU)...
Pfizer Inc announced that the Phase 3 INTORSECT study...
15 May 2012 | By Pfizer
Pfizer Inc announced that the Phase 3 INTORSECT study...
New data will be presented on targeted cancer treatments from…
14 May 2012 | By Pfizer
New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories...
First treatment to demonstrate superior benefit in a Phase 3…
27 January 2012 | By Pfizer
First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...
Investigator research on several pfizer compounds to be presented...
7 November 2011 | By Pfizer
Investigator research on several pfizer compounds to be presented...
Pfizer Inc. announced data from the pivotal Phase 3 AXIS…
18 May 2011 | By Pfizer
Pfizer Inc. announced data from the pivotal Phase 3 AXIS 1032 trial. Patients with previously treated advanced RCC, axitinib extended progression-free survival...
